A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.
Zydus Cadila has launched the most economical brand of remdesivir, licensed from Gilead Sciences, Inc., in India. Priced at INR2,800 ($37) per 100mg injection, Remdac is nearly 50% cheaper than the highest-cost Indian brand of the drug.
In June 2020, Zydus entered into a non-exclusive agreement with Gilead to manufacture and sell remdesivir, which has emergency use...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
